NR3C2 and chronic kidney disease: In a subgroup analysis of the DAPA-CKD (Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease) trial, a renal protection effect was achieved with or without spironolactone or eplerenone at baseline, and the incidence of hyperkalemia tended to be lower in patients receiving MR antagonists (hazard ratio, 0.87; 95% CI, 0.69–1.10) [157].